We are live on
!
Find out more
HCM
Horan Capital Management Portfolio holdings
AUM
$794M
1-Year Est. Return
30.86%
This Fund
S&P 500
This Quarter
Est. Return
+3.08%
1 Year Est. Return
+30.86%
3 Year Est. Return
+69.18%
5 Year Est. Return
+124.11%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$18.2M
(+4.2%)
Cap. Flow
+$5.66M
Cap. Flow
% of AUM
1.24%
Top 10 Holdings %
Top 10 Hldgs %
45.82%
Holding
86
New
5
Increased
17
Reduced
46
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.74M |
| 2 |
CVS Health
CVS
|
+$6.5M |
| 3 |
Biogen
BIIB
|
+$3.72M |
| 4 |
Schwab US Aggregate Bond ETF
SCHZ
|
+$2.66M |
| 5 |
Gilead Sciences
GILD
|
+$1.91M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tapestry
TPR
|
+$7.81M |
| 2 |
Fossil Group
FOSL
|
+$4.28M |
| 3 |
Merck
MRK
|
+$2.87M |
| 4 |
US Bancorp
USB
|
+$789K |
| 5 |
T. Rowe Price
TROW
|
+$767K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.17% |
| 2 | Healthcare | 17.27% |
| 3 | Technology | 14.9% |
| 4 | Industrials | 10.1% |
| 5 | Consumer Discretionary | 9.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Berkshire Hathaway Class B
BRK.B
$1.08T
| $28.9M | 6.33% |
170,737
+2,846
| +2% | +$473K |
|
2
Alphabet (Google) Class C
GOOG
$4.19T
| $24.2M | 5.3% |
533,060
+10,340
| +2% | +$473K |
|
3
Amazon
AMZN
$2.87T
| $23.6M | 5.17% |
488,400
-2,520
| -0.5% | -$120K |
|
4
Visa
V
$712B
| $21.5M | 4.71% |
229,789
+4,529
| +2% | +$420K |
|
5
Microsoft
MSFT
$3.81T
| $19.9M | 4.36% |
289,415
-2,594
| -0.9% | -$178K |
|
|
6
Gilead Sciences
GILD
$181B
| $19.8M | 4.33% |
279,734
+28,734
| +11% | +$1.91M |
|
7
Apple
AAPL
$4.67T
| $18.4M | 4.03% |
512,108
-1,492
| -0.3% | -$55.2K |
|
8
Citigroup
C
$223B
| $18.4M | 4.03% |
275,329
+9,340
| +4% | +$573K |
|
9
Walmart Inc
WMT
$820B
| $17.4M | 3.8% |
688,272
-3,150
| -0.5% | -$80K |
|
10
Wells Fargo
WFC
$262B
| $17.2M | 3.76% |
310,402
+15,558
| +5% | +$834K |
|
11
Procter & Gamble
PG
$334B
| $16.6M | 3.62% |
190,103
-1,562
| -0.8% | -$138K |
|
12
GE Aerospace
GE
$355B
| $14.2M | 3.1% |
109,526
-1,021
| -0.9% | -$140K |
|
13
Emerson Electric
EMR
$86.6B
| $13.7M | 3% |
230,125
-3,090
| -1% | -$183K |
|
|
14
Bristol-Myers Squibb
BMY
$136B
| $13.5M | 2.96% |
242,881
+142,170
| +141% | +$7.74M |
|
15
Bank of America
BAC
$436B
| $13.3M | 2.92% |
550,044
-3,300
| -0.6% | -$76.9K |
|
16
Union Pacific
UNP
$183B
| $11.5M | 2.51% |
105,278
-1,490
| -1% | -$162K |
|
|
17
US Bancorp
USB
$97.3B
| $10.7M | 2.34% |
205,736
-15,319
| -7% | -$789K |
|
18
Cisco
CSCO
$433B
| $9.96M | 2.18% |
318,268
-1,558
| -0.5% | -$50.8K |
|
19
iShares Core US Aggregate Bond ETF
AGG
$138B
| $9.93M | 2.17% |
90,689
+14,088
| +18% | +$1.54M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $9.39M | 2.05% |
38,627
-90
| -0.2% | -$21.1K |
|
21
Pfizer
PFE
$159B
| $9.39M | 2.05% |
294,605
-2,899
| -1% | -$91.4K |
|
22
Oracle
ORCL
$435B
| $9.06M | 1.98% |
180,753
-1,220
| -0.7% | -$55.6K |
|
23
Polaris
PII
$3.63B
| $8.69M | 1.9% |
94,232
+6,693
| +8% | +$574K |
|
|
24
CVS Health
CVS
$119B
| $8.53M | 1.86% |
105,976
+82,324
| +348% | +$6.5M |
|
25
Johnson & Johnson
JNJ
$646B
| $8.31M | 1.82% |
62,818
-3,734
| -6% | -$476K |
|
Similar funds
DBC
BII
HCMNY
DK
AVAX
IVA
LCM
WEC
Horan Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Horan Capital Management held 86 positions worth $457M, up 4.2% from $439M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Horan Capital Management's Q2 2017 filing shows 5 new, 17 increased, 46 reduced and 18 closed positions. Its largest new stake was Schwab US Aggregate Bond ETF: 101,830 shares worth $2.66M. The largest sale was Tapestry, an estimated $7.81M.
By sector, the portfolio is most concentrated in Financials at 25% of assets, down from 25% a quarter earlier, followed by Healthcare and Technology.
- Horan Capital Management's largest Q2 2017 buy was Schwab US Aggregate Bond ETF: 101,830 shares worth $2.66M.
- Horan Capital Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $7.74M increase.
- Horan Capital Management's biggest Q2 2017 reduction was US Bancorp, cutting an estimated $789K.
- Horan Capital Management fully exited Tapestry in Q2 2017, selling an estimated $7.81M.
- Horan Capital Management's ten largest holdings make up 46% of its $457M portfolio in Q2 2017.
- Horan Capital Management opened 5 new positions and closed 18 in Q2 2017.
- Horan Capital Management's portfolio value rose 4.2% quarter-over-quarter to $457M.
Based on Horan Capital Management's 13F filing for Q2 2017, filed 17 Jul 2017.